Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa)

Nephrology Dialysis Transplantation

Volumn 29, Issue 2, 2014, Pages 400-405

  Hammer, Fabian ^a   Krane, Vera ^a   Störk, Stefan ^a   Röser, Christoph ^b   Hofmann, Kirsten ^b   Pollak, Nils ^a   Allolio, Bruno ^a   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

aldosterone; dialysis; end stage renal disease; left ventricular hypertrophy; mineralocorticoid receptor antagonist; spironolactone

Indexed keywords

MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM; SPIRONOLACTONE;

ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ALDOSTERONE; DIALYSIS; END STAGE RENAL DISEASE; LEFT VENTRICULAR HYPERTROPHY; MINERALOCORTICOID RECEPTOR ANTAGONIST; SPIRONOLACTONE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84896712069     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft409     Document Type: Article

References (40)

1. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-2047
2. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
3. Cice G, Di Benedetto A, D'Isa S et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebocontrolled trial. J Am Coll Cardiol 2010; 56: 1701-1708
4. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebocontrolled trial. J Am Coll Cardiol 2003; 41: 1438-1444
5. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079-1084
6. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
7. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774
8. Krane V, Heinrich F, Meesmann M et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol 2009; 4: 394-400
9. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767
10. Rossi GP, Sacchetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045
11. Muiesan ML, Salvetti M, Paini A et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534
12. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838
13. Gaddam K, Corros C, Pimenta E et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study. Hypertension 2010; 55: 1137-1142
14. Catena C, Colussi G, Lapenna R et al. Long-Term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension [Research Support, Non-U.S. Gov't] 2007; 50: 911-918
15. Edwards NC, Steeds RP, Stewart PM et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512
16. Guder G, Bauersachs J, Frantz S et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115: 1754-1761
17. Swedberg K, Eneroth P, Kjekshus J et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990; 66: 40D-44D
18. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
19. Palmer BR, Pilbrow AP, Frampton CM et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008; 29: 2489-2496
20. Drechsler C, Ritz E, Tomaschitz A et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. Eur Heart J 2012; 34: 578-587
21. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
22. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
23. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
24. Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with endstage renal disease on hemodialysis: Is it safe?. Clin Cardiol 2010; 33: 604-608
25. Baker WL, White WB. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012; 46: 889-894
26. Gross E, Rothstein M, Dombek S et al. Effect of spironolactone on blood pressure and the renin-Angiotensin-Aldosterone system in oligo-Anuric hemodialysis patients. AmJ Kidney Dis. 2005; 46: 94-101
27. Vukusich A, Kunstmann S, Varela C et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1380-1387
28. Shavit L, Neykin D, Lifschitz M et al. Effect of eplerenone on blood pressure and the renin-Angiotensin-Aldosterone system in oligo-Anuric chronic hemodialysis patients-A pilot study. Clin Nephrol [Multicenter Study]. 2011; 76: 388-395
29. Taheri S, Mortazavi M, Pourmoghadas A et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transplant Organ Transplant [Randomized Controlled Trial Research Support, Non-U.S.: Gov't] 2012; 23: 507-512
30. Taheri S, Mortazavi M, Shahidi S et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transplant 2009; 20: 392-397
31. McGill RL, Biederman RW, Getts RT et al. Cardiac magnetic resonance imaging in hemodialysis patients. J Nephrol 2009; 22: 367-372
32. Pocock SJ. Current issues in the design and interpretation of clinical trials. Br Med J (Clin Res Ed). 1985; 290: 39-42
33. Matsumoto Y, Kageyama S, Yakushigawa T et al. Long-Term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009; 114: 32-38
34. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
35. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
36. Foley RN, Curtis BM, Randell EW et al. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol [Multicenter Study Randomized Controlled Trial]. 2010; 5: 805-813
37. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845
38. De Souza F, Muxfeldt E, Fiszman R et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension [Clinical Trial Research Support, Non-U.S. Gov't]. 2010; 55: 147-152
39. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000
40. Nitta K, Akiba T, Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med [Comment Letter] 2003; 115: 250